血液学の最新論文（2018年7月リリース分）New reports on Hematology
Leukemia
- Blood Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? 132(4):351-361 Boissel N, Baruchel A
- Blood Treatment strategies for adolescent and young adult patients with acute myeloid leukemia. 132(4):362-368 O'Dwyer K, Freyer DR, Horan JT
- Blood Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. 132(4):393-404 Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM
- Blood Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. 132(4):405-412 Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, Ten Bosch JVW, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Foà R, Locatelli F, Kaspers GJL
- Blood USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. 132(4):423-434 Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D
- Blood NUT midline carcinoma with leukemic presentation mimicking CD34-positive acute leukemia. 132(4):456 Li W, Chastain K
- Blood Cuplike nuclear morphology in pediatric B-cell acute lymphoblastic leukemia. 132(4):457 Richardson AI, Li W
- Blood International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. 132(3):264-276 Hrusak O, de Haas V, Stancikova J, Vakrmanova B, Janotova I, Mejstrikova E, Capek V, Trka J, Zaliova M, Luks A, Bleckmann K, Möricke A, Irving J, Konatkowska B, Alexander TB, Inaba H, Schmiegelow K, Stokley S, Zemanova Z, Moorman AV, Rossi JG, Felice MS, Dalla-Pozza L, Morales J, Dworzak M, Buldini B, Basso G, Campbell M, Cabrera ME, Marinov N, Elitzur S, Izraeli S, Luria D, Feuerstein T, Kolenova A, Svec P, Kreminska O, Rabin KR, Polychronopoulou S, da Costa E, Marquart HV, Kattamis A, Ratei R, Reinhardt D, Choi JK, Schrappe M, Stary J
- Blood Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. 132(3):307-320 Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, Lang F, Zang T, Kröger T, Ernst T, Kögler G, Krieg A, Lüdeke S, Kunkel H, Rodrigues Moita AJ, Kassack MU, Marquardt V, Opitz FV, Oldenburg M, Remke M, Babor F, Grez M, Hochhaus A, Borkhardt A, Groth G, Nagel-Steger L, Jose J, Kurz T, Gohlke H, Hansen FK, Hauer J
- Blood Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. 132(2):170-178 Hasan MK, Yu J, Widhopf GF 2nd, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ
- Blood Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. 132(2):187-196 Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C
- Blood How and when I do allogeneic transplant in CLL. 132(1):31-39 Gribben JG
- Blood Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. 132(1):67-77 Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T
- Blood T-cell prolymphocytic leukemia negative for surface CD3 and CD45. 132(1):111 Thakral B, Wang SA
- Br J Haematol Congenital acute myeloid leukaemia with KMT2A rearrangement. 182(2):169 Wan Ariffin E, Jones H, Bhatnagar N
- Br J Haematol Neonatal leukaemia. 182(2):170-184 Roberts I, Fordham NJ, Rao A, Bain BJ
- Br J Haematol Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome. 182(2):200-211 Tunstall O, Bhatnagar N, James B, Norton A, O'Marcaigh AS, Watts T, Greenough A, Vyas P, Roberts I, Wright M; British Society for Haematology
- Br J Haematol Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). 182(2):245-250 Konuma T, Yanada M, Yamasaki S, Kuwatsuka Y, Fukuda T, Kobayashi T, Ozawa Y, Uchida N, Ota S, Hoshino T, Takahashi S, Kanda Y, Ueda Y, Takanashi M, Kanda J, Ichinohe T, Atsuta Y, Yano S
- Br J Haematol t(6;9)(p23;q34.1) acute myeloid leukaemia with cup-like blasts. 182(1):9 Bories C, Boyer T
- Br J Haematol JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. 182(1):78-85 Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A
- Haematologica Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia? 103(7):1096-1098 Brown JR
- Haematologica The chromatin-remodeling factor CHD4 is required for maintenance of childhood acute myeloid leukemia. 103(7):1169-1181 Heshmati Y, Türköz G, Harisankar A, Kharazi S, Boström J, Dolatabadi EK, Krstic A, Chang D, Månsson R, Altun M, Qian H, Walfridsson J
- Haematologica Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. 103(7):1209-1217 Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum
- Haematologica Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial. 103(7):e288-e292 Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, Patrick K, Hancock J, Samarasinghe S, Linch DC, Moorman AV, Goulden N, Vora A, Mansour MR
- Haematologica Combination of common and novel rare NUDT15 variants improves predictive sensitivity of thiopurine-induced leukopenia in children with acute lymphoblastic leukemia. 103(7):e293-e295 Zhu Y, Yin D, Su Y, Xia X, Moriyama T, Nishii R, Liao F, Zhang S, Guo X, Hou Q, Ai Y, Zhou X, Sun S, Zhang D, Zhang Y, Lin C, Deng Y, Lu X, Wang Y, Ma Z, Wang H, Liu B, Yang L, Zhang W, Yang JJ, Shu Y, Gao J, Xu H
- Haematologica Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. 103(7):e300-e303 Andersen MA, Eriksen CT, Brieghel C, Biccler JL, Cunha-Bang CD, Helleberg M, Niemann CU
- Haematologica Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. 103(7):e304-e306 Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S
- Haematologica Immune failure, infection and survival in chronic lymphocytic leukemia. 103(7):e329 Crassini KR, Best OG, Mulligan SP
- Haematologica Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark. 103(7):e330 Andersen MA, Niemann CU
- J Clin Oncol Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. 36(19):1973-1980 Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG
- J Clin Oncol Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia. 36(19):1991-1993 Letai A
- Lancet Oncol Towards home-based treatment for acute promyelocytic leukaemia, with caution. 19(7):846–847 Francesco Lo-Coco, Laura Cicconi
- Lancet Oncol FLT3 inhibitors for relapsed or refractory acute myeloid leukaemia. 19(7):849–850 Eytan M Stein
- Lancet Oncol Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. 19(7):871–879 Hong-Hu Zhu, De-Pei Wu, Xin Du, Xi Zhang, Lin Liu, Jun Ma, Zong-Hong Shao, Han-Yun Ren, Jian-Da Hu, Kai-Lin Xu, Jing-Wen Wang, Yong-Ping Song, Mei-Yun Fang, Juan Li, Xiao-Yan Yan, Xiao-Jun Huang
- Lancet Oncol Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. 19(7):889–903 Jorge Cortes, Alexander E Perl, Hartmut Döhner, Hagop Kantarjian, Giovanni Martinelli, Tibor Kovacsovics, Philippe Rousselot, Björn Steffen, Hervé Dombret, Elihu Estey, Stephen Strickland, Jessica K Altman, Claudia D Baldus, Alan Burnett, Alwin Krämer, Nigel Russell, Neil P Shah, Catherine C Smith, Eunice S Wang, Norbert Ifrah, Guy Gammon, Denise Trone, Deborah Lazzaretto, Mark Levis
- Leukemia New drugs in AML: uses and abuses. 32(7):1479–1481 Estey EH, Gale RP, Sekeres MA
- Leukemia Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet? 32(7):1482-1492 Tawana K, Drazer MW, Churpek JE
- Leukemia Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. 32(7):1515-1528 Maruffi M, Sposto R, Oberley MJ, Kysh L, Orgel E
- Leukemia Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. 32(7):1598-1608 Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH
- Leukemia Chromothripsis in acute myeloid leukemia: biological features and impact on survival. 32(7):1609-1620 Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G
- Leukemia Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. 32(7):1621–1630 Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H
- Leukemia Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. 32(7):1643–1656 Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S
- Leukemia Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. 32(7):1657–1669 Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C
Lymphoma
- Blood A tale of two mantle cell lymphomas. 132(4):347-348 Martin P
- Blood The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice? 132(4):376-384 Flerlage JE, Metzger ML, Bhakta N
- Blood A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. 132(4):413-422 Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E
- Blood Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. 132(3):245-253 Schmitz N, Lenz G, Stelljes M
- Blood How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. 132(3):254-263 Gopal S, Gross TG
- Blood Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. 132(3):293-306 Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM
- Blood Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven. 132(3):339-340 Adams HJA, Kwee TC
- Blood Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. 132(2):179-186 Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, Di Rocco A, Conconi A, Stathis A, Cavalli F, Bellei M, Cozens K, Porro E, Giovanella L, Johnson PW, Zucca E
- Blood Getting to transplant in Hodgkin lymphoma: BVB. 132(1):1-3 Gordon LI
- Blood Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. 132(1):9-16 Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B
- Blood Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade? 132(1):17-22 Carbone A, Gloghini A, Carlo-Stella C
- Blood Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. 132(1):40-48 LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R
- Blood A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. 132(1):49-58 Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G
- Br J Haematol How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma? 182(2):163-164 Maraldo MV, Illidge TM
- Br J Haematol Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. 182(2):212-221 Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM
- Br J Haematol Guideline for the management of mantle cell lymphoma. 182(1):46-62 McKay P, Leach M, Jackson B, Robinson S, Rule S
- Br J Haematol A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma. 182(1):63-70 McKay P, Leach M, Jackson B, Robinson S, Rule S
- Haematologica Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. 103(7):1182-1190 Horn H, Kohler C, Witzig R, Kreuz M, Leich E, Klapper W, Hummel M, Loeffler M, Trümper L, Spang R, Rosenwald A, Ott G; Molecular Mechanisms in Malignant Lymphomas (MMML) Network Project
- Haematologica The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. 103(7):1191-1197 Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko YH, Martinez V, Montoto S, Chiattone C, Moskowitz A, Spina M, Biasoli I, Manni M, Federico M; International T-cell Project Network
- Haematologica Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients. 103(7):e296-e299 Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J
- J Clin Oncol Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care. 36(20):2009-2011 Merryman RW, LaCasce AS
- J Clin Oncol Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. 36(20):2024-2034 Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators
- J Clin Oncol Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia. 36(19):1991-1993 Letai A
Myeloma
- Blood Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population. 132(2):232-235 Bryant D, Tapper W, Weston-Bell NJ, Bolomsky A, Song L, Xu S, Collins AR, Zojer N, Sahota SS
- Blood The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. 132(1):59-66 Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N
- Br J Haematol Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients. 182(2):165-167 Larocca A, D'Agostino M, Boccadoro M
- Br J Haematol A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. 182(2):222-230 O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS
- Br J Haematol Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. 182(2):231-244 Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R
- Br J Haematol Induction therapy for multiple myeloma: more is not necessarily better! 182(1):7-8 Kumar L, Ganesan P
- Br J Haematol Resistance to proteasome inhibitors and other targeted therapies in myeloma. 182(1):11-28 Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, Pitson SM
- Br J Haematol Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. 182(1):71-77 Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA
- Haematologica Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. 103(7):1218-1228 Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP
- Haematologica The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study. 103(7):e311-e314 Oortgiesen BE, Azad R, Hemmelder MH, Kibbelaar RE, Veeger NJGM, de Vries JC, van Roon EN, Hoogendoorn M
- J Clin Oncol Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. 36(20):2012-2016 Bladé J, Rosiñol L, Cibeira MT, Fernández de Larrea C
- J Clin Oncol Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. 36(20):2035-2043 Dimopoulos M, Weisel K, van de Donk NWCJ, Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la Rubia J, Mateos MV, Ardizzoia A, Kueenburg E, Collins S, Di Micco A, Rosettani B, Li Y, Bacon P, Sonneveld P
- Lancet Oncol Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. 19(7):953–964 Philippe Moreau, Maria-Victoria Mateos, James R Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A Keith Stewart
- Leukemia Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? 32(7):1500-1514 Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I
- Leukemia Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. 32(7):1542–1560 Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P
- Leukemia Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? 32(7):1561-1566 Pawlyn C, Loehr A, Ashby C, Tytarenko R, Deshpande S, Sun J, Fedorchak K, Mughal T, Davies FE, Walker BA, Morgan GJ
- Leukemia Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. 32(7):1567–1574 Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG
SCT
- Blood Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. 132(3):245-253 Schmitz N, Lenz G, Stelljes M
- Blood Getting to transplant in Hodgkin lymphoma: BVB. 132(1):1-3 Gordon LI
- Blood Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. 132(1):9-16 Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B
- Blood How and when I do allogeneic transplant in CLL. 132(1):31-39 Gribben JG
- Br J Haematol Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). 182(2):245-250 Konuma T, Yanada M, Yamasaki S, Kuwatsuka Y, Fukuda T, Kobayashi T, Ozawa Y, Uchida N, Ota S, Hoshino T, Takahashi S, Kanda Y, Ueda Y, Takanashi M, Kanda J, Ichinohe T, Atsuta Y, Yano S
- Br J Haematol Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. 182(1):71-77 Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA
- Haematologica Complication free survival long-term after hemopoietic cell transplantation in thalassemia. 103(7):1094-1096 Angelucci E
- Haematologica Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience. 103(7):1143-1149 Rahal I, Galambrun C, Bertrand Y, Garnier N, Paillard C, Frange P, Pondarré C, Dalle JH, de Latour RP, Michallet M, Steschenko D, Moshous D, Lutz P, Stephan JL, Rohrlich PS, Yakoub-Agha I, Bernaudin F, Piguet C, Aladjidi N, Badens C, Berger C, Socié G, Dumesnil C, Castex MP, Poirée M, Lambilliotte A, Thomas C, Simon P, Auquier P, Michel G, Loundou A, Agouti I, Thuret I
- Haematologica Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. 103(7):1229-1234 Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M
HSC
- Blood Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. 132(3):245-253 Schmitz N, Lenz G, Stelljes M
- Blood Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. 132(1):9-16 Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B
- Br J Haematol Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). 182(2):245-250 Konuma T, Yanada M, Yamasaki S, Kuwatsuka Y, Fukuda T, Kobayashi T, Ozawa Y, Uchida N, Ota S, Hoshino T, Takahashi S, Kanda Y, Ueda Y, Takanashi M, Kanda J, Ichinohe T, Atsuta Y, Yano S
- Br J Haematol Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. 182(1):71-77 Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA
- Haematologica Complication free survival long-term after hemopoietic cell transplantation in thalassemia. 103(7):1094-1096 Angelucci E
- Haematologica Setd2 regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation. 103(7):1110-1123 Zhou Y, Yan X, Feng X, Bu J, Dong Y, Lin P, Hayashi Y, Huang R, Olsson A, Andreassen PR, Grimes HL, Wang QF, Cheng T, Xiao Z, Jin J, Huang G
- Haematologica Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience. 103(7):1143-1149 Rahal I, Galambrun C, Bertrand Y, Garnier N, Paillard C, Frange P, Pondarré C, Dalle JH, de Latour RP, Michallet M, Steschenko D, Moshous D, Lutz P, Stephan JL, Rohrlich PS, Yakoub-Agha I, Bernaudin F, Piguet C, Aladjidi N, Badens C, Berger C, Socié G, Dumesnil C, Castex MP, Poirée M, Lambilliotte A, Thomas C, Simon P, Auquier P, Michel G, Loundou A, Agouti I, Thuret I
Anemia
- Blood Internuclear bridging outside of primary myelodysplasia and congenital dyserythropoietic anemia. 132(2):236 Rojas-Martínez JA, Morales-Camacho RM
- Br J Haematol Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia. 182(1):10 Chonat S, McLemore ML, Bunting ST, Nortman S, Zhang K, Kalfa TA
- Haematologica Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction. 103(7):1136-1142 Tewari S, Renney G, Brewin J, Gardner K, Kirkham F, Inusa B, Barrett JE, Menzel S, Thein SL, Ward M, Rees DC
- Haematologica Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes. 103(7):1150-1159 Giudice V, Banaszak LG, Gutierrez-Rodrigues F, Kajigaya S, Panjwani R, Ibanez MDPF, Rios O, Bleck CK, Stempinski ES, Raffo DQ, Townsley DM, Young NS
- Lancet Haematol A new option for treating CKD-associated anaemia in children. 5(7):e270 The Lancet Haematology
- Lancet Haematol Intravenous iron in post-bariatric abdominoplasty anaemia: a pragmatic approach. 5(7):e277-e278 Khalafallah AA
- Lancet Haematol Intravenous iron sucrose versus oral iron administration for the postoperative treatment of post-bariatric abdominoplasty anaemia: an open-label, randomised, superiority trial in Brazil. 5(7):e310-e320 Montano-Pedroso JC, Bueno Garcia E, Alcântara Rodrigues de Moraes M, Francescato Veiga D, Masako Ferreira L
- N Engl J Med Case 22-2018: A 64-Year-Old Man with Progressive Leg Weakness, Recurrent Falls, and Anemia. 379(3):282-289 Bennett SE, Schmitt WP, Stanford FC, Baron JM
Bone marrow failure
- このキーワードに関連した論文はありません
ITP
- このキーワードに関連した論文はありません